Objective We searched for evidence on mycophenolate mofetil(MMF) as a treatment for patients with diffuse proliferative lupus nephritis. Methods We attempted to find the current best evidence by searching The Cochrane Library(Issue 4, 2005), MEDLINE(1990 to June 2007), CMB(1980 to December 2006), CNKI(1979 to October 2007). We critically appraised the available evidence. Results Four systematic reviews and 6 randomized controlled trials of high quality were available. MMF and prednisolone were found to be an effective continuous induction-maintenance treatment for diffuse proliferative lupus nephritis. MMF was associated with less drug toxicity. Conclusion Given the current evidence and our clinical experience, and considering the patient and the values and preferences of his family,MMF was given at 1 g daily in combination with steroids at the beginning. No obvious adverse effects occurred during 3 months of follow-up.
【摘要】 目的 发现提示早期Ⅴ型狼疮性肾炎（lupus nephritis，LN）的指标。 方法 2004年 1月-2009年11月24例经肾活检诊断为Ⅴ型LN患者，与同期50例膜性肾病伴抗核抗体（antinuclear antibody，ANA）阳性患者、50例膜性肾病ANA阴性患者，以及13例膜性肾病ANA阳性且肾组织荧光为“满堂亮”患者的一般资料、肾病表现、肾脏病理以及实验室指标进行比较。 结果 Ⅴ型LN与膜性肾病ANA阴性的患者相比，两组的性别、起病年龄、血红蛋白、补体水平、内皮和系膜增殖的比例等有明显差异。膜性肾病ANA阳性患者的临床和病理表现更接近于ANA阴性的膜性肾病，但其性别比仍以女性居多。而膜性肾病ANA阳性伴“满堂亮”的患者在性别、肾病表现、血红蛋白、补体水平等方面与Ⅴ型LN更为接近。 结论 膜性肾病ANA阳性患者具有异质性，其中肾脏病理表现为“满堂亮”的患者可能系早期Ⅴ型LN。【Abstract】 Objective To find out the clinical and pathological characteristics of early pure class Ⅴ lupus nephritis (LN). Methods A total of 24 patients with pure class Ⅴ LN diagnosed between January 2004 and November 2009 were included, and were compared with 50 antinuclear antibody (ANA)-positive patients with membranous nephropathy (MN) and 50 ANA-negative patients with MN. The clinical and pathological characteristics, laboratory test results were compared between the two groups. Then, 13 patients with "full house" fluorescence in renal biopsy specimens were chosen from the group of ANA-positive membranous nephropathy, whose clinical characteristics and laboratory test were compared with class Ⅴ LN patients. Results There were significant differences in sex ratio, age, positive rate of hepatitis B surface antigen (HBsAg), levels of hemoglobin, white blood cell, platelet,complement, endothelial and mesangial proliferation between class Ⅴ LN and ANA-negative MN group. However, the sex ratio, levels of white blood cell, platelet were similar between class Ⅴ LN and ANA-positive MN group. The renal biopsy specimens in patients with ANA-positive MN with "full house" fluorescence were similar with those in the patients with class Ⅴ LN in sex ratio, renal injury, hemoglobin and complement and the positive rate of hepatitis B surface antigen. Conclusion The demographic information and clinical manifestations in patients with class Ⅴ LN were similar to those in patients with ANA positive MN, especially in the patients wiht ANA-positive MN with "full house" fluorescence in renal biopsy specimens.
Objective To assess the effectiveness and safety of mycophenolate mofetil (MMF) in the treatment of proliferative lupus nephritis. Methods We searched CBM (November 1979 to February 2006), Chinese Cochrane Centre Database (2005), The Cochrane Library (Issue 4, 2005), MEDLINE (November 1966 to February 2006) and EMBASE (1975 to February 2006) for randomize controlled trials. Data were extracted and analyzed using The Cochrane Collaboration’s RevMan 4.2.7. Results Nine randomize controlled trials involving 512 patients met the inclusion criteria. The meta-analysis showed that the total clinical effective rate and complete remission rate were not significantly higher for MMF than for cyclophosphamide, azathioprine, or both. Renal survival rate and relapse rate of MMF were not significantly different from those for cyclophosphamide, azathioprine, or both. Patient survival rate and safety of MMF were significantly improved compared with cyclophosphamide, azathioprine, or both. Conclusion More large-scale multi-center randomized trials are needed to investigate the role of MMF in the treatment of proliferative lupus nephritis.
目的:探讨狼疮肾炎(lupus nephritis,LN)患者肾小球滤过率(glomerular filtration rate,GFR)与其病理分型及临床指标的关系。方法:检测39例狼疮肾炎患者行肾活检前一周内的血清肌酐(Scr)、血尿素氮(BUN)、血清白蛋白、24h尿蛋白定量、补体C3、C4、抗双链DNA(dsDNA)抗体滴度、体重指标,同时记录患者年龄和SLEDAI积分,利用MDRD-7公式计算GFR。结果:LN各病理类型间Scr、BUN、GFR的差异均无统计学意义(P gt;0.05),血清白蛋白各病理类型间差异有统计学意义(p lt;0.05)。相关分析提示LN患者的24 h尿蛋白量与GFR存在负相关关系,相关系数(r=-0.330, P=0.040),LN患者的GFR与SLEDAI积分、补体C3、C4水平、抗dsDNA抗体滴度均未见明显相关性。结论:LN的病理分型结果不能代替GFR对肾功能的评估;LN患者24h尿蛋白定量一定程度上可以对肾功能做出评估;SLEDAI积分、C3、C4以及抗dsDNA抗体滴度水平不能反映患者肾脏损害程度。
ObjectiveTo systematically review the diagnostic value of anti-C1q antibodies for lupus nephritis (LN) in Chinese population. MethodsWe electronically searched databases including PubMed, EMbase, CNKI, The Cochrane Library, VIP and WanFang Data for diagnostic accuracy studies of anti-C1q antibodies for LN in Chinese population from inception to 1st March, 2015. Two reviewers independently screened literature, extracted data and assessed the risk bias of included studies by QUADAS tool. Then, meta-analysis was performed by Meta-DiSc 1.4 software and Stata 11.0 software. ResultsA total of 11 studies involving 1 084 systemic lupus erythematosus (SLE) patients were included. Among them, 474 patients were LN. The results of meta-analysis showed that:the pooled sensitivity, specificity, diagnostic odds ratio, positive likelihood ratio, and negative likelihood ratio of anti-C1q in the diagnosis of LN were 0.67 (95%CI 0.63 to 0.71), 0.69 (95%CI 0.65 to 0.74), 5.09 (95%CI 3.29 to 7.85), 2.18 (95%CI 1.75 to 2.72), and 0.48 (95%CI 0.39 to 0.60), respectively. The area under the curve (AUC) of SROC was 0.749 6 and the Q index value was 0.693 1. The average missed diagnosis rate was 33.0% and the misdiagnosis rate was 31.0%. ConclusionCurrent evidence indicates that anti-C1q antibodies may have some value in the diagnosis of LN. Because of the high missed diagnosis rate and the misdiagnosis rate, it could not be used to diagnose LN alone, and it only could be used as an adjuvant diagnostic indicator for LN. Due to the limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusion.
Objective To explore the potential mechanism of the occurrence and development of lupus nephritis (LN) and identify key biomarkers and immune-related pathways associated with the progression of LN. Methods We downloaded a dataset from the Gene Expression Omnibus database. By analyzing the differential expression of genes and performing weighted gene co-expression network analysis (WGCNA), as well as Gene Ontology enrichment, Disease Ontology enrichment, and Kyoto Encyclopedia of Genes and Genomes pathway enrichment, we explored the biological functions of differentially expressed genes in LN. Using three machine learning models, namely LASSO regression, support vector machine, and random forest, we identified the hub genes in LN, and constructed a line diagram diagnosis model based on the hub genes. The diagnostic accuracies of the hub genes were evaluated using the receiver operating characteristic curve, and the relationship between known marker gene sets and hub gene expression was analyzed using single sample gene set enrichment analysis. Results We identified a total of 2297 differentially expressed genes. WGCNA generated 7 co-expression modules, among which the cyan module had the highest correlation with LN. We obtained 347 target genes by combining differential genes. Using the three machine learning methods, LASSO regression, support vector machine, and random forest, we identified three hub genes (CLC, ADGRE4P, and CISD2) that could serve as potential biomarkers for LN. The area under the receiver operating characteristic curve (AUC) analysis showed that these three hub genes had significant diagnostic value (AUCCLC=0.718, AUCADGRE4P=0.813, AUCCISD2=0.718). According to single sample gene set enrichment analysis, the hub genes were mainly associated with apoptosis, glycolysis, metabolism, hypoxia, and tumor necrosis factor-α-nuclear factor-κB-related pathways. Conclusions By combining WGCNA and machine learning techniques, three hub genes (CLC, ADGRE4P, and CISD2) that may be involved in the occurrence and development of LN are identified. These genes have the potential to aid in the early clinical diagnosis of LN and provide insight into the mechanisms underlying LN progression.